UONDDL
TGTX icon

University of Notre Dame du Lac’s TG Therapeutics TGTX Stock Holding History

University of Notre Dame du Lac’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-302,761
Closed -$2.48M – 87
2017
Q4 		$2.48M Buy
+302,761
New +$2.65M 0.52% 65
2017
Q3 		– Sell
-211,927
Closed -$2.13M – 82
2017
Q2 		$2.13M Buy
+211,927
New +$2.37M 0.63% 71

Other funds holding TGTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
CCI
Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

University of Notre Dame du Lac's TGTX Position: Q1 2018 in Review

University of Notre Dame du Lac sold out of TG Therapeutics (TGTX) in Q1 2018, closing a stake of 302,761 shares — an estimated $2.48M sold.

University of Notre Dame du Lac first reported a position in TGTX in Q2 2017 and held it in 2 quarters. The position peaked at $2.48M in Q4 2017. 125 funds tracked by Wall St. Rank hold TGTX as of Q1 2018.

  • University of Notre Dame du Lac reported no remaining TG Therapeutics position as of Q1 2018 after selling out during the quarter.
  • University of Notre Dame du Lac sold 302,761 TG Therapeutics shares in Q1 2018, an estimated $2.48M.
  • University of Notre Dame du Lac first reported a position in TG Therapeutics in Q2 2017 and held it in 2 quarters.
  • University of Notre Dame du Lac's TG Therapeutics position peaked at $2.48M in Q4 2017.
  • 125 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2018.

Based on University of Notre Dame du Lac's 13F filing for Q1 2018, filed 15 May 2018.